GlassScriptPhysician profile
Noemi Pimentel
NPI 1538643218
$11,256.91
in general payments reported to CMS, 2019-2025
52 companies · $2,380 in 2025
The $2,380 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,802 · 2022: $1,742 · 2023: $2,091 · 2024: $2,242 · 2025: $2,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,712.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,637.79 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,210.83 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,209.55 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Biohaven Pharmaceuticals, INC. | $1,137.85 | 2021 | |
| Amgen INC. | $676.42 | 2021-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $619.10 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $483.45 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $435.38 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $385.47 | 2022 | |
| Astellas Pharma US INC | $358.33 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $345.57 | 2021-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $325.48 | 2022-2025 | Proclaim, Infinity |
| Axsome Therapeutics, INC. | $261.18 | 2024-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.64 | 2021-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $179.01 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noemi Pimentel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.